Tordoff Diana M, Lunn Mitchell R, Flentje Annesa, Atashroo Diana, Chen Bertha, Dastur Zubin, Lubensky Micah E, Capriotti Matthew, Obedin-Maliver Juno
The PRIDE Study/PRIDEnet, Stanford University School of Medicine, Palo Alto, California, USA.
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.
Andrology. 2025 Mar;13(3):600-609. doi: 10.1111/andr.13703. Epub 2024 Jul 16.
There are limited data on pelvic pain among transgender men and gender diverse people, and the impact of testosterone on pelvic pain is poorly understood.
Characterize the prevalence and correlates of chronic pelvic pain (CPP) among transgender men and gender diverse people and examine the association between testosterone use and CPP.
We used 2020-2022 data from The Population Research in Identity and Disparities for Equality (PRIDE) Study, an online prospective cohort study of sexual and gender minority adults in the United States, to conduct complementary cross-sectional and longitudinal analyses. Our primary outcome was self-reported CPP lasting 3 months or longer measured using the Michigan Body Map.
Among 2579 transgender men and gender diverse people assigned female at birth included in our sample, 457 (18%) reported CPP. CPP correlates included: inflammatory bowel disease, irritable bowel syndrome (IBS), kidney stones, pelvic inflammatory disease, polycystic ovary syndrome (PCOS), uterine fibroids, current hormonal intrauterine device use, prior pregnancy, vaginal delivery, hysterectomy, and oophorectomy. Individuals with CPP reported a high prevalence of IBS (37%), PCOS (20%), uterine fibroids (9%), post-traumatic stress disorder (51%), and severe depression and anxiety symptoms (42% and 25%, respectively). Current testosterone use was associated with a 21% lower prevalence of CPP (adjusted prevalence ratio (aPR) 0.79, 95% confidence interval [CI]: 0.65-0.96). In longitudinal analyses (N = 79), 15 (19%) participants reported any CPP after initiating testosterone: eight (56%) of whom reported CPP prior to testosterone initiation, and seven (47%) who reported new-onset CPP.
The relationship between CPP and testosterone is complex. Although testosterone use was associated with a lower prevalence of CPP, some transgender and gender diverse individuals experienced new-onset pelvic pain after testosterone initiation. Given the significant impact that CPP can have on mental health and quality of life, future research must examine the role of testosterone in specific underlying etiologies of CPP and identify potential therapies.
关于跨性别男性和性别多样化人群盆腔疼痛的数据有限,且睾酮对盆腔疼痛的影响尚不清楚。
描述跨性别男性和性别多样化人群中慢性盆腔疼痛(CPP)的患病率及其相关因素,并研究睾酮使用与CPP之间的关联。
我们使用了美国性与性别少数群体成年人在线前瞻性队列研究“平等身份与差异人口研究”(PRIDE研究)2020 - 2022年的数据,进行补充性横断面和纵向分析。我们的主要结局是使用密歇根身体地图测量的自我报告的持续3个月或更长时间的CPP。
在我们样本中纳入的2579名出生时被指定为女性的跨性别男性和性别多样化人群中,457人(18%)报告有CPP。CPP的相关因素包括:炎症性肠病、肠易激综合征(IBS)、肾结石、盆腔炎、多囊卵巢综合征(PCOS)、子宫肌瘤、当前使用含激素宫内节育器、既往怀孕、阴道分娩、子宫切除术和卵巢切除术。患有CPP的个体报告IBS的患病率较高(37%)、PCOS(20%)、子宫肌瘤(9%)、创伤后应激障碍(51%)以及严重抑郁和焦虑症状(分别为42%和25%)。当前使用睾酮与CPP患病率降低21%相关(调整患病率比(aPR)0.79,95%置信区间[CI]:0.65 - 0.96)。在纵向分析(N = 79)中,15名(占19%)参与者在开始使用睾酮后报告有任何CPP:其中8名(占56%)在开始使用睾酮之前就报告有CPP,7名(占47%)报告有新发CPP。
CPP与睾酮之间的关系很复杂。虽然使用睾酮与CPP患病率较低相关,但一些跨性别和性别多样化个体在开始使用睾酮后出现了新发盆腔疼痛。鉴于CPP会对心理健康和生活质量产生重大影响,未来研究必须研究睾酮在CPP特定潜在病因中的作用,并确定潜在治疗方法。